Inhibition of corneal graft rejection by antioxidants

Information

  • Research Project
  • 6693923
  • ApplicationId
    6693923
  • Core Project Number
    R41EY015028
  • Full Project Number
    1R41EY015028-01
  • Serial Number
    15028
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/2003 - 21 years ago
  • Project End Date
    8/31/2004 - 20 years ago
  • Program Officer Name
    HELMSEN, RALPH J
  • Budget Start Date
    9/15/2003 - 21 years ago
  • Budget End Date
    8/31/2004 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/15/2003 - 21 years ago
Organizations

Inhibition of corneal graft rejection by antioxidants

DESCRIPTION (provided by applicant): Corneal transplantation is the most common form of tissue allotransplantation (47,000 cases per year). However, 15% of the grafts are rejected within a year in "high risk" patients. In "low risk" patients, immunosuppressive drug treatment is associated with induction of cataracts, glaucoma and infections. In fact, despite the high rate of success, more corneal allografts rejections fail per year in the United States than any other form of solid-tissue transplant. It is therefore necessary to develop new treatments to prevent high-risk corneal graft and to avoid utilization of immunosuppressive agents in all patients. Eukarion has developed a series of synthetic mimetics of the antioxidant enzymes superoxide dismutase and catalase. These compounds have been shown to promote tissue preservation and to block deleterious immune responses in a number of animal models. Particularly, they prevent autoimmune diseases and skin graft rejection without widespread immunosuppression and toxicity. Furthermore, they show protective effect in various topical applications. Eukarion compounds have been shown to be efficacious in 3 processes leading to corneal graft rejection e.g: i) preservation of tissue before transplantation, ii) corneal neovascularization, iii) inflammation/immune rejection. Here, we propose to test the effect of these compounds on corneal graft rejection following ex vivo treatment of the graft and/or topical treatment of recipient. We plan: 1) to synthetize and screen analogs of these compounds for their cellular permeability and stability. 2) to test selected compounds for their ability to prevent/retard allogenic corneal transplantation. We will identify a lead molecule for topical treatment delaying/preventing corneal allograft rejection for further development. This will hopefully provide the therapeutic community with a molecule that would be efficacious in acute corneal transplant rejection without the side effects associated with current therapies.

IC Name
NATIONAL EYE INSTITUTE
  • Activity
    R41
  • Administering IC
    EY
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    187250
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    867
  • Ed Inst. Type
  • Funding ICs
    NEI:187250\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    EUKARION, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    WOBURN
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01801
  • Organization District
    UNITED STATES